Myriad Genetics, Inc.
NASDAQ:MYGNMedical - Diagnostics & Research
+$0.14 today
- Market cap
- $530.45M
- Beta
- 1.64
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$4.27
Volume 1.26M
Average 1.81M
MYGN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Myriad Genetics, Inc.NASDAQ: MYGN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $27.1M fell 1.5% year over year, ahead of the -7.7% change in trailing-twelve-month research & development. Sequentially, it rose 6.3% from the prior quarter. Over 3 fiscal years it compounded at +7.7% a year.
Context
- Research & development amounted to 13.0% of revenue in FY2025, down 0.6 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -1.5% holds above the trailing-twelve-month pace of -7.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 106.8M USD
- Year-over-year change
- -5.8%
- 4-year CAGR
- +6.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 106.8M | -5.8% |
| FY2024 | 2024-12-31 | 113.4M | +27.8% |
| FY2023 | 2023-12-31 | 88.7M | +3.9% |
| FY2022 | 2022-12-31 | 85.4M | +4.3% |
| FY2021 | 2021-12-31 | 81.9M | — |
Research & Development vs competitors
How MYGN compares with its peers on the latest reported figures
- MYGN's LTM Mar 2026 research & development of $106.4M is the 4th highest of the 10 companies compared; the peer median is $59.21M.
- Its year-over-year change of -7.7% is the lowest of 10, against a peer median of +11.9%.
- Research & development amounts to 12.8% of revenue for MYGN, versus a peer median of 17.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $787.38M | +56.9% | +25.4% | 29.1% | |
| LTM Sep 2026 | $386.67M | +7.6% | -0.9% | 30.2% | |
| LTM Jun 2026 | $194.67M | +5.5% | -0.4% | 9.3% | |
| LTM Mar 2026 | $106.4M | -7.7% | +7.7% | 12.8% | |
| LTM Jun 2026 | $93.37M | +31.8% | +20.4% | 16.6% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $59.21M | +38.6% | — | 14.9% |
| LTM Mar 2026 | $55.69M | +11.9% | +23.1% | 17.4% | |
| LTM Mar 2026 | $52.16M | +6.9% | -8.2% | 80.9% | |
| LTM Jun 2026 | $38.17M | +9.5% | +6.9% | 5.0% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $17.59M | +68.3% | +29.6% | 902.4% |
| Peer median (excluding MYGN) | $59.21M | +11.9% | +13.6% | 17.4% | |
Competitors are the stored peer set for MYGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 690.6M | 678.4M | 753.2M | 837.6M | 824.5M |
| Cost of Revenue | 197.6M | 202M | 236.2M | 252.2M | 247.9M |
| Gross Profit | 493M | 476.4M | 517M | 585.4M | 576.6M |
| Gross Margin | 71.4% | 70.2% | 68.6% | 69.9% | 69.9% |
| Research & Development | 81.9M | 85.4M | 88.7M | 113.4M | 106.8M |
| Selling, General & Admin | 537.8M | 514.7M | 572.9M | 560M | 537.6M |
| Operating Expenses | 683.5M | 617M | 774.4M | 708.9M | 644.4M |
| Depreciation & Amortization | 62.8M | 52.7M | 61.9M | 61.2M | 53.7M |
| EBITDA | 12.3M | (84.7M) | (197.4M) | (59.5M) | (330.9M) |
| EBITDA Margin | 1.8% | -12.5% | -26.2% | -7.1% | -40.1% |
| Operating Income | (190.5M) | (140.6M) | (257.4M) | (123.5M) | (67.8M) |
| Operating Margin | -27.6% | -20.7% | -34.2% | -14.7% | -8.2% |
| Interest Income | 700K | 2.6M | 2.5M | 1.7M | 1.8M |
| Interest Expense | 6.6M | 3.2M | 2.9M | 2.8M | 10.5M |
| Other Income / Expenses | 133.4M | (16.9M) | (4.8M) | (35.5M) | (327.3M) |
| Income Before Tax | (57.1M) | (140.6M) | (262.2M) | (123.5M) | (395.1M) |
| Pre-Tax Margin | -8.3% | -20.7% | -34.8% | -14.7% | -47.9% |
| Income Tax Expense | (29.9M) | (28.6M) | 1.1M | 3.8M | (29.2M) |
| Net Income | (27.2M) | (112M) | (263.3M) | (127.3M) | (365.9M) |
| Net Margin | -3.9% | -16.5% | -35.0% | -15.2% | -44.4% |
| EPS (Basic) | (0.35) | (1.39) | (3.18) | (1.41) | (3.96) |
| EPS (Diluted) | (0.35) | (1.39) | (3.18) | (1.41) | (3.96) |
| Weighted Avg Shares | 77.71M | 80.58M | 82.8M | 90.6M | 93.3M |
| Weighted Avg Shares (Diluted) | 78M | 80.6M | 82.8M | 90.6M | 93.3M |
Myriad Genetics, Inc.
NASDAQ:MYGN
Intrinsic Alpha fair value
Locked
Current Price
$5.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.